alexa Hepatocellular Carcinoma with McCune Albright Syndrome | Open Access Journals
ISSN: 2167-0889
Journal of Liver
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Hepatocellular Carcinoma with McCune Albright Syndrome

Satoshi Kotani1*, Shuichi Sato2, Naruaki Kohge3, Kousuke Tsukano3, Sayaka Ogawa3, Satoshi Yamanouchi3, Ryusaku Kusunoki3, Masahito Aimi3, Youichi Miyaoka1, Hirofumi Fujishiro3, Tomohiko Yamamoto4 and Hideyuki Ohnuma4

1Department of Endoscopy, Shimane Prefectural Central Hospital, Japan

2Department of Gastroenterology and Hepatology, Shimane University School of Medicine, Japan

3Department of Gastroenterology, Shimane Prefectural Central Hospital, Japan

4Department of Pathology, Shimane Prefectural Central Hospital, Japan

*Corresponding Author:
Satoshi Kotani
Department of Endoscopy, Shimane Prefectural Central Hospital
4-1-1 Himebara, Izumo 693-8555, Shimane, Japan
Tel: 81-853-225111
E-mail: ksoattaonsihi@gmail.com

Received date: May 08, 2017; Accepted date: May 13, 2017; Published date: May 15, 2017

Citation: Satoshi Kotani, Shuichi Sato, Naruaki Kohge, Kousuke Tsukano, Sayaka Ogawa, et al. (2017) The Accuracy of a Non-Invasive Liver Fibrosis Evaluation Method, Shear Wave Elastography: A Retrospective Pilot Study. J Liver 6:212. doi: 10.4172/2167-0889.1000212

Copyright: © 2017 Kotani S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Liver

Abstract

Cyprostate acetate (CPA) has been used in the treatment of hyper sexuality, which is considered as carcinogenic agent and its use has been prohibited for children. We presented young patient having hepatocellular carcinoma (HCC) with medication history of CPA during childhood, which arose from normal background liver without virus infections and other causes of liver dysfunction. The patient had multiple tumours in the liver, and only the largest one was diagnosed as HCC and other resected ones were hemangioma and hamartoma.

Keywords

Chronic liver disease; Liver fibrosis; Shear wave elastography

Introduction

Liver fibrosis and cirrhosis occur as a result of chronic liver inflammation caused by viral, autoimmune, and metabolic diseases. It is very important to assess the degree of liver fibrosis to determine the prognosis and to decide whether treatment should be pursued. Liver biopsy has been considered the gold standard for assessment of liver fibrosis and cirrhosis so far [1,2]. However, it is an invasive procedure associated with morbidities, such as pain via examination, intraabdominal bleeding, and perforation of the intestine [3]. In addition, liver biopsy has the limitations of sampling error and intra- and interobserver variability [4-6]. Because of these problems, liver biopsy is not an ideal method for repeated assessment of disease progression in patients with chronic liver diseases. Therefore, a non-invasive and accurate liver fibrosis assessment method is needed as an alternative to liver biopsy. Liver stiffness measurements using elastography for the non-invasive evaluation of liver fibrosis have been developed in the last few years [7-10]. Transient elastography (TE, Fibroscan®) is a useful test in almost any patient in whom a clinician wishes to stage liver fibrosis. However, technical limitations of the test preclude its use in patients with ascites and in obese individuals, in whom either the test cannot be performed or the results of the test are not reliable. Shear wave elastography (SWE) can calculate the velocity of shear waves, and this velocity can be used to assess tissue stiffness by the formula E=ρc2. E is tissue elasticity (kPa), ρ is tissue density (kg/m3), and c is shear wave velocity (m/s) [11]. Several reports indicate that SWE is more accurate than TE in assessing significant fibrosis [11-13]. However, the usefulness of SWE has not been fully investigated.

The purpose of this study was to evaluate the diagnostic accuracy of SWE technology from Toshiba for the assessment of liver fibrosis in patients with liver disease.

Methods

Patients

Between December 2014 and March 2016, 68 patients were admitted to our hospital to undergo liver biopsy. Among these, 54 consecutive patients underwent SWE measurement with Aplio500 (Toshiba Medical Systems Corporation, Tochigi, Japan) at the time of liver biopsy. We gave each patient a full explanation of the study procedures prior to study entry, and the patients provided written informed consent at enrolment. This retrospective human study was approved by the Ethics Committee of the Shimane Prefectural Central Hospital, and complied with all of the provisions of the Declaration of Helsinki.

Measurement of shear wave elastography

We use the Aplio500 ultrasound (US) system with a convex broadband probe (3.5 MHz). SWE measurements were performed on the right lobe of the liver, through the intercostal spaces, with patients in the supine position with the right hand abducted. The upper edge of the SWE box was placed about 2 cm from the body surface. The SWE box was away from intrahepatic vessels and the gallbladder. A circular region of interest (ROI) of size 1cm diameter was placed on the most homogeneous area within the SWE box. Each measurement was made at least twice, and the average shear wave velocity was recorded. We also measured the thickness of the body wall. No patient had ascites at the time of the SWE measurement.

Liver biopsy and histological assessment

The same intercostal space was used for both SWE measurement and liver biopsy. Liver biopsy and SWE measurement were performed on the same day. SWE measurements and liver biopsies were carried out consecutively by three physicians (SK, KT, and NK). An 18-gauge automatic biopsy gun (ACECUT, TSK LABORATORY, Tochigi, Japan) was used under US guidance. Liver biopsy specimens were read by two expert pathologists (TY and HO). Histological stages of liver fibrosis were diagnosed according to the new Inuyama classification of chronic hepatitis: F0, no fibrosis; F1, portal fibrosis widening; F2, portal fibrosis widening with bridging fibrosis; F3, bridging fibrosis plus lobular distortion; and F4, liver cirrhosis [14]. Liver inflammatory activity stages were staged as A0, no liver inflammation; A1, mild degree of liver inflammation; A2, moderate degree of liver inflammation; A3, severe degree of liver inflammation [14]. In this study, F3 and F4 were defined as severe fibrosis.

Statistical Analysis

A receiver operating characteristic (ROC) curve was constructed to assess the accuracy of the SWE measurement and to identify an optimal cut-off value. Continuous variables were compared with the Kruskal-Wallis test. Correlation between groups was evaluated with Spearman’s rank correlation coefficient test. Multiple regression analysis was carried out with a stepwise method. A P-value<0.05 was considered statistically significant. Analysis was performed with SPSS version 21 software for Windows (IBM, Armonk, USA).

Results

Patient characteristics

The baseline characteristics of the patients (n=54) are shown in Table 1. The study population contained 20 men (37.0%) and 34 women (63.0%) with a median age of 65 years (range, 26-86 years). The final diagnosis of the 54 patients was as follows: hepatitis C virus infection in 13 cases (24.1%), non-alcoholic steatohepatitis (NASH) in 10 cases (18.5%), hepatitis B virus infection in 9 cases (16.7%), alcoholic liver disease (ALD) in 6 cases (11.1%), primary biliary cirrhosis (PBC) in 5 cases (9.3%), and other (including autoimmune hepatitis, drug-induced liver injury, elevated liver function tests of unknown cause, and metastatic liver cancer) in 11 cases (20.4%). The fibrosis score was F0 for 9 cases (16.7%), F1 for 18 cases (33.3%), F2 for 11 cases (20.4%), F3 for 9 cases (16.7%), and F4 for 7 cases (13.0%).

Age (range), years 65 (26-86)
Sex, male/female 20/34
Etiology of liver disease, n (%)
 Chronic hepatitis B 9 (16.7%)
 Chronic hepatitis C 13 (24.1%)
 Non-alcoholic steatohepatitis 10 (18.5%)
 Alcoholic liver disease 6 (11.1%)
 Primary biliary cirrhosis 5 (9.4%)
 Other 11 (20.4%)
Liver histological findings
 Fibrosis, 0/1/2/3/4 9/18/11/9/7
 Activity, 0/1/2/3 6/27/16/5

Table 1: Patient characteristics (n=54). Data are expressed as number or median (range or percentage).

Correlation between shear wave velocity and liver fibrosis

The average shear wave velocity ranged from 1.51 to 3.69 m/s, with a median [first and third quartiles] of 2.01 [1.75-2.39] m/s. The correlation between shear wave velocity and fibrosis stage obtained by liver biopsy was analyzed (Figure 1).

leukemia-wave-velocity

Figure 1: Box-and-whisker plot of the shear wave velocity for each fibrosis stage of the liver in 54 patients who underwent liver biopsy. The top and bottom of the boxes are the first and third quartiles. The length of the box represents the interquartile range, covering 50% of the levels. The lines through the middle of the box and values besides the box indicate the median level. The error bars are the minimum and maximum levels.

The median shear wave velocity in each type of fibrosis was 1.77 m/s in F0, 1.81 m/s in F1, 1.88 m/s in F2, 2.39 m/s in F3, and 3.11 m/s in F4. The shear wave velocity increased significantly according to the progression of liver fibrosis (r=0.679, P<0.001). We analyzed the diagnostic accuracy of shear wave velocity to predict severe fibrosis and liver cirrhosis by ROC. For predicting severe fibrosis, the area under the ROC curve (AUC) was 0.931 at an optimal cut-off value of 2.145 m/s (sensitivity, 100%; specificity, 81.6%; P<0.001). For predicting liver cirrhosis, the AUC was 0.916 at an optimal cut-off value of 2.475 m/s (sensitivity, 85.7%; specificity, 85.1%; P<0.001) (Figure 2).

leukemia-curve analyses

Figure 2: Receiver operating characteristic (ROC) curve analyses for predicting severe fibrosis (F3 or F4) and cirrhosis (F4). (a) F0-2 vs. F3-4. (b) F0-3 vs. F4.

Multiple regression analysis

To determine the independent factors affecting fibrosis, multiple regression analysis was conducted. Multiple regression analysis included age, body mass index (BMI), thickness of the body wall, shear wave velocity, aspartate aminotransferase (AST) level, alanine aminotransferase (ALT) level, platelet count, serum albumin level, fibrosis 4 index (FIB-4 index), and aspartate aminotransferase to platelet ratio index (APRI).

Table 2 demonstrates that the effects of shear wave velocity and platelet count were statistically significant. The regression equation was as follows: Y=-0.688+0.664X1-0.293X2, where X1 is shear wave velocity (m/s) and X2 is platelet count (× 109/L).

Unstandardized Coefficients Standardized Coefficient
Factor B value Standard error Beta value T test P-value
Constant -0.688 0.606    --- -1.135 0.262
Shear wave velocity 1.587 0.221 0.664 7.172 0.000
Platelet count -0.005 0.002 -0.293 -3.169 0.003

Table 2: Multiple regression analysis results.

These results suggested that the contribution of these two predictors to the regression equation was in the following descending order: shear wave velocity>platelet count.

Correlation between shear wave velocity and laboratory parameters

Shear wave velocity was positively correlated with the level of AST, ALT, FIB-4 index, APRI, BMI and the thickness of the body wall (Table 3). The thickness of the body wall showed the highest correlation (r=0.524, P<0.001), followed by APRI (r=0.486, P<0.001), FIB-4 index (r=0.455, P<0.005), BMI (r=0.406, P<0.005), AST level (r=0.366, P<0.05), liver inflammation (r=0.303, P<0.05) and ALT level (r=0.294, P<0.05). It was negatively correlated with platelet count (r=-0.312, P<0.05). No correlation was found between shear wave velocity and age or serum albumin level.

Variable r P-value
Age 0.192 0.165
Liver fibrosis 0.679 <0.001
Liver inflammation 0.303 <0.05
AST (U/L) 0.366 <0.05
ALT (U/L) 0.294 <0.05
Platelet count (× 109/L) -0.312 <0.05
Serum albumin (g/L) -0.058 0.676
FIB-4 index 0.455 <0.005
APRI 0.486 <0.001
BMI (kg/m2) 0.406 <0.005
Thickness of the body wall (mm) 0.524 <0.001
AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; APRI: Aspartate aminotransferase to platelet ratio index; BMI: Body mass index; FIB-4 index: Fibrosis 4 index

Table 3: Correlation between groups was evaluated with Spearman’s rank correlation coefficient test. Correlation between the shear wave velocity and laboratory parameters.

Discussion

In this study, we evaluated the diagnostic accuracy of SWE with Aplio500 for liver fibrosis in liver disease. The results demonstrated that SWE was reliable for assessing severe fibrosis and cirrhosis.

Methods to assess the development of liver fibrosis are valuable. Morphological changes are observed on ultrasonography, computed tomography and magnetic resonance imaging. Irregular surface and atrophy of the liver [15-18], dilatation of the portal and hepatic veins, splenomegaly and ascites are often observed in patients with advanced chronic liver disease. However, the diagnostic accuracy of these findings is not high. Recently, various biological markers based on clinical and biological data have been reported to be useful predictors of liver fibrosis in patients with liver disease. These include hyaluronic acid, type IV collagen 7S, type III procollagenN-peptide (P-III-P) levels, fucosylated haptoglobin and Mac2 binding protein. In addition, combinations of biochemical markers, such as in the APRI, the FIB-4 index and the FibroTest, have been reported to be associated with liver fibrosis [19-24]. In recent years, advances in imaging technology have enabled quantitative and noninvasive measurements of liver stiffness with various US-based elastographic methods, including Real-time Tissue Elastography (RTE), TE, Acoustic Radiation Force Impulse Imaging (ARFI), and SWE. Among these methods, SWE is a new realtime technique that uses measurements of acoustically generated tissue shear wave propagation velocity to derive estimates of liver stiffness. RTE, TE, and ARFI have been evaluated in several meta-analyses for their roles in staging liver fibrosis, and were shown to be useful methods with high accuracy for the diagnosis of cirrhosis but intermediate accuracy for differentiating between mild and moderate liver fibrosis [25]. TE, however, has limitations, because in a considerable percentage of patients with obesity, it was unsuccessful. In addition, in spite of the limited function of the TE machine, which only measures TE, the machine is very expensive. Other machines that do not measure TE include two techniques, imaging examination and estimation of liver elasticity. Aplio500 for SWE was just released in 2014, so few reports have evaluated the diagnostic accuracy of SWE using Aplio500. Iijima et al. evaluated the diagnostic accuracy of SWE for liver fibrosis with Aplio500, and they also demonstrated the reliability of SWE. However, the cut-off value of cirrhosis in their report was 2.20 m/s, which was significantly lower than our cut-off value [12]. Thus, we have investigated the reason for this difference. A comparison of the patient groups in Iijima’s report and in our case revealed that while the cases of chronic hepatitis C in Iijima’s reports had accounted for about two-thirds of the population, in our report, hepatitis C represented only 24% of the population. In addition, Iijima’s population contained only once case of NASH, while there were 10 cases of NASH in our report. Thus, it is considered that the difference in the proportions of patients with these diseases appeared to be the reason for the difference in the cut-off values. As described in the Results section, SWE was correlated with BMI and the thickness of the body wall. Furthermore, patients with NASH tend to have greater BMI and body wall thickness compared to patients with other diseases. Therefore, in patients with NASH, there is a possibility that SWE will be higher than the degree of fibrosis. Grgurevic et al. also reported that the reliability of SWE was significantly lower in patients with high BMI [26].

A limitation of this study is that the number of patients is small. Therefore, we could not verify the correlation between liver fibrosis and SWE for each disease group. It is necessary to accumulate more cases to verify it.

Conclusion

Although an accurate evaluation might be difficult in obese patients, especially those with NASH, SWE is a useful method to evaluate liver fibrosis noninvasively.

Conflict of Interest

The authors state that they have no Conflict of Interest (COI).

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 63
  • [From(publication date):
    August-2017 - Jun 24, 2017]
  • Breakdown by view type
  • HTML page views : 45
  • PDF downloads :18
 
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

agrifoodaquavet@omicsonline.com

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

clinical_biochem@omicsonline.com

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

business@omicsonline.com

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

chemicaleng_chemistry@omicsonline.com

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

environmentalsci@omicsonline.com

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

engineering@omicsonline.com

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

generalsci_healthcare@omicsonline.com

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

genetics_molbio@omicsonline.com

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

immuno_microbio@omicsonline.com

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

omics@omicsonline.com

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

materialsci@omicsonline.com

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

mathematics_physics@omicsonline.com

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

medical@omicsonline.com

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

neuro_psychology@omicsonline.com

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

pharma@omicsonline.com

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

social_politicalsci@omicsonline.com

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version